Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields)

被引:47
作者
Porat, Yaara [1 ]
Giladi, Moshe [1 ]
Schneiderman, Rosa S. [1 ]
Blat, Roni [1 ]
Shteingauz, Anna [1 ]
Zeevi, Einav [1 ]
Munster, Mijal [1 ]
Voloshin, Tali [1 ]
Kaynan, Noa [1 ]
Tal, Orna [1 ]
Kirson, Eilon D. [2 ]
Weinberg, Uri [3 ]
Palti, Yoram [2 ]
机构
[1] Novocure Ltd, Preclin Res Dept, Haifa, Israel
[2] Novocure Ltd, Haifa, Israel
[3] Novocure GmbH, Luzern, Switzerland
来源
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS | 2017年 / 123期
关键词
Cancer Research; Issue; 123; Tumor Treating Fields; TTFields; inovitro; glioma; ovarian cancer; frequency scan; ALTERNATING ELECTRIC-FIELDS; PHYSICIANS CHOICE CHEMOTHERAPY; IN-VITRO; LUNG-CANCER; COMBINATION; DISRUPTION; VIVO; GLIOBLASTOMA; THERAPY; SYSTEM;
D O I
10.3791/55820
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Tumor Treating Fields (TTFields) are an effective treatment modality delivered via the continuous, noninvasive application of low-intensity (1-3 V/cm), alternating electric fields in the frequency range of several hundred kHz. The study of TTFields in tissue culture is carried out using the TTFields in vitro application system, which allows for the application of electric fields of varying frequencies and intensities to ceramic Petri dishes with a high dielectric constant (epsilon > 5,000). Cancerous cell lines plated on coverslips at the bottom of the ceramic Petri dishes are subjected to TTFields delivered in two orthogonal directions at various frequencies to facilitate treatment outcome tests, such as cell counts and clonogenic assays. The results presented in this report demonstrate that the optimal frequency of the TTFields with respect to both cell counts and clonogenic assays is 200 kHz for both ovarian and glioma cells.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields])
    Shams, Shadi
    Patel, Chirag B.
    JOURNAL OF MOLECULAR CELL BIOLOGY, 2022, 14 (08)
  • [22] Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo
    Davidi, Shiri
    Jacobovitch, Sara
    Shteingauz, Anna
    Martinez-Conde, Antonia
    Braten, Ori
    Tempel-Brami, Catherine
    Zeevi, Einav
    Frechtel-Gerzi, Roni
    Ene, Hila
    Dor-On, Eyal
    Voloshin, Tali
    Tzchori, Itai
    Haber, Adi
    Giladi, Moshe
    Kinzel, Adrian
    Weinberg, Uri
    Palti, Yoram
    CANCERS, 2022, 14 (12)
  • [23] Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines
    Fishman, Hila
    Monin, Roni
    Dor-On, Eyal
    Kinzel, Adrian
    Haber, Adi
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    JOURNAL OF NEURO-ONCOLOGY, 2023, 163 (01) : 83 - 94
  • [24] The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts
    Nancy Ann Oberheim-Bush
    Wenyin Shi
    Michael W. McDermott
    Alexander Grote
    Julia Stindl
    Leonardo Lustgarten
    Journal of Neuro-Oncology, 2022, 158 : 453 - 461
  • [25] Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region
    Anadkat, Milan J.
    Lacouture, Mario
    Friedman, Adam
    Horne, Zachary D.
    Jung, Jae
    Kaffenberger, Benjamin
    Kalmadi, Sujith
    Ovington, Liza
    Kotecha, Rupesh
    Abdullah, Huda Ismail
    Grosso, Federica
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [26] Tumor Treating Fields (TTFields) induce homologous recombination deficiency in ovarian cancer cells, thus mitigating drug resistance
    Berckmans, Yani
    Ene, Hila M.
    Ben-Meir, Kerem
    Martinez-Conde, Antonia
    Wouters, Roxanne
    van den Ende, Bieke
    Van Mechelen, Sara
    Monin, Roni
    Frechtel-Gerzi, Roni
    Gabay, Hila
    Dor-On, Eyal
    Haber, Adi
    Weinberg, Uri
    Vergote, Ignace
    Giladi, Moshe
    Coosemans, An
    Palti, Yoram
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [27] Association of tumor treating fields (TTFields) therapy with overall survival in newly diagnosed glioblastoma
    Shah, Siddharth
    Nag, Aiswarya
    Lucke-Wold, Brandon
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025,
  • [28] Case report: durable response of gliomatosis cerebri with concurrent tumor-treating fields (TTFields) and chemoradiotherapy treatment
    Desjarlais, Alex M.
    Miller, Ryan
    Ali, Ayesha S.
    Niazi, Muneeb Z.
    Cappelli, Louis
    Glass, Jon
    Farrell, Christopher J.
    Shi, Wenyin
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (06)
  • [29] Temperature and Impedance Variations During Tumor Treating Fields (TTFields) Treatment
    Gentilal, Nichal
    Abend, Eyal
    Naveh, Ariel
    Marciano, Tal
    Balin, Igal
    Telepinsky, Yevgeniy
    Miranda, Pedro Cavaleiro
    FRONTIERS IN HUMAN NEUROSCIENCE, 2022, 16
  • [30] Evaluating the therapeutic effect of tumor treating fields (TTFields) by monitoring the impedance across TTFields electrode arrays
    Li, Xing
    Oziel, Moshe
    Rubinsky, Boris
    PEERJ, 2022, 10